Atlas Trials

Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)

Clinical trial NCT01096992 · COMPLETED

Trial details

NCT number
NCT01096992
Sponsor
M.D. Anderson Cancer Center
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Leukemia
Start date
2010-04-19
Primary completion
2017-03-31
Enrollment
51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.